Article
Pharmacology & Pharmacy
Yahiya Y. Syed
Summary: Lotilaner ophthalmic solution 0.25% is a drug that selectively inhibits mites and has been approved for the treatment of Demodex blepharitis in the USA. It is currently undergoing clinical trials in China for the treatment of Demodex-induced meibomianitis.
Article
Ophthalmology
Roberto Gonzalez-Salinas, Paul Karpecki, Elizabeth Yeu, Mark Holdbrook, Stephanie N. Baba, Juan Carlos Ceballos, Martha Massaro-Corredor, Claudia Corredor-Ortega, Nallely Ramos-Betancourt, Hugo Quiroz-Mercado
Summary: The use of lotilaner ophthalmic solution has shown to be safe and effective in treating Demodex blepharitis. The improvement in collarette grade and mite density observed during the treatment period persisted for at least two months following treatment cessation.
CONTACT LENS & ANTERIOR EYE
(2022)
Article
Ophthalmology
Ian Benjamin Gaddie, Eric D. Donnenfeld, Paul Karpecki, Patrick Vollmer, Gregg J. Berdy, Jared D. Peterson, Aimee R. P. Edell, Blake Simmons, William E. Whitson, Joseph B. Ciolino, Stephanie N. Baba, Mark Holdbrook, Jose Trevejo, John Meyer, Elizabeth Yeu
Summary: The study demonstrated that lotilaner ophthalmic solution 0.25% was safe and effective for the treatment of Demodex blepharitis compared to vehicle control, achieving higher cure rates for collarettes, mite eradication, erythema, and overall composite cure. Compliance with the treatment regimen was high, and most patients found the drops to be comfortable.
Article
Ophthalmology
Elizabeth Yeu, Mark Holdbrook, Stephanie N. Baba, Juan Carlos Ceballos, Martha Massaro-Corredor, Claudia Corredor-Ortega, Nallely Ramos-Betancourt, Hugo Quiroz-Mercado, Roberto Gonzalez-Salinas
Summary: This study evaluated the efficacy and safety of lotilaner ophthalmic solution, 0.25% eyedrops in the treatment of Demodex blepharitis. The results showed a significantly higher proportion of participants achieving collar cure, mite eradication, and composite cure compared to the control group.
OCULAR IMMUNOLOGY AND INFLAMMATION
(2023)
Article
Ophthalmology
Roberto Gonzalez-Salinas, Elizabeth Yeu, Mark Holdbrook, Stephanie N. Baba, Juan Carlos Ceballos, Martha Massaro-Corredor, Claudia Corredor-Ortega, Nallely Ramos-Betancourt, Hugo Quiroz-Mercado
Summary: Topical treatment with 0.25% lotilaner ophthalmic solution was effective in reducing collarettes and mite density in patients with Demodex blepharitis.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
(2021)
Article
Ophthalmology
Ceyhun Arici, Burak Mergen, Hrisi Bahar Tokman, Ayse Yildiz Tas, Edip Tokuc, Yesim Ozturk Bakar, Afsun Sahin
Summary: The study found that the diagnostic efficiency of using 10% potassium hydroxide with light microscopy for detecting Demodex eyelid infestation was superior in quantifying mites compared to using alcohol and IVCM.
OCULAR IMMUNOLOGY AND INFLAMMATION
(2022)
Article
Ophthalmology
Na An, Xiuhong Dou, Ni Yin, Haiqing Lu, Jie Zheng, Xianning Liu, Hua Yang, Xiuping Zhu, Xianghua Xiao
Summary: This pilot study evaluated the efficacy of digital polymerase chain reaction (PCR) detection of Demodex for the diagnosis of Demodex blepharitis. The results showed that the accuracy of digital PCR detection was 71.6%, while the mite counting method had an accuracy of 75%. Combining both methods improved the accuracy to 77.3%. The study concluded that digital PCR detection is a potentially accurate method for diagnosing Demodex blepharitis, especially when a sufficient number of eyelashes cannot be effectively collected.
CURRENT EYE RESEARCH
(2023)
Article
Ophthalmology
Roberto Gonzalez-Salinas, Elizabeth Yeu, Mark Holdbrook, Stephanie N. Baba, Juan Carlos Ceballos, Martha Massaro-Corredor, Claudia Corredor-Ortega, Nallely Ramos-Betancourt, Hugo Quiroz-Mercado
Summary: Topical lotilaner ophthalmic solution, 0.25%, showed promising efficacy for treating Demodex blepharitis over 4 weeks, with significant improvements in collarette grade and mite density. The treatment was well tolerated with no adverse events, and effects were durable up to Day 90. Randomized controlled studies are needed to confirm these results.
JOURNAL OF OPHTHALMOLOGY
(2021)
Article
Ophthalmology
William Trattler, Paul Karpecki, Yuna Rapoport, Ehsan Sadri, Scott Schachter, Walter O. Whitley, Elizabeth Yeu
Summary: Through a retrospective study, it was found that Demodex blepharitis has a high prevalence among patients seeking eye care in the United States and is likely underdiagnosed. Patients undergoing anti-inflammatory treatment for dry eye disease had a higher prevalence, and those using tea tree oil had even higher prevalence.
CLINICAL OPHTHALMOLOGY
(2022)
Article
Ophthalmology
Leslie O'Dell, Damon S. Dierker, Douglas K. Devries, Jaclyn Garlich, Walter Whitley, Mark Holdbrook, Stephanie N. Baba, Elizabeth Yeu
Summary: Demodex blepharitis has a significant negative impact on daily activities, mental, and physical well-being of afflicted patients, with symptoms including dry eyes, itchiness, and irritation, and many patients being conscious of their eyes all day.
CLINICAL OPHTHALMOLOGY
(2022)
Article
Medicine, General & Internal
Zeeshan Kamil, Qirat Qurban, Khalid Mahmood
Summary: The study aimed to observe the efficacy of a single injection of Bevacizumab in decreasing eyelid margin vascularization and improving tear film level. Eleven patients with refractory blepharitis showed reduced lid margin vascularity and improved tear film level one month post Bevacizumab injection, indicating its effectiveness as a treatment.
ANNALS OF KING EDWARD MEDICAL UNIVERSITY LAHORE PAKISTAN
(2021)
Article
Ophthalmology
Charlotte Boel, Elianne Westerveld, Daniella Kloos, Fleur Goezinne
Summary: By examining the hair follicles of eyelashes, it was found that 94% of patients were infected with Demodex, with an average of 3 mites per hair shaft. The presence of Demodex was significantly correlated with cylindrical dandruff, but not with collarettes or symptoms of blepharitis. These results suggest that a non-invasive diagnostic technique can be used by ophthalmologists and optometrists in outpatient clinical practice to quickly and easily identify Demodex.
CLINICAL OPHTHALMOLOGY
(2023)